
Year-End Late-Stage Pipeline Review
Sanofi is pleased to invite investors and analysts to participate in a year-end late-stage pipeline review by R&D management on Tuesday, December 16, 2025.
Press Releases
December 15, 2025
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
December 15, 2025
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
December 11, 2025
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
Upcoming Events
12Dec
2025
Leerink Partners POLARxPRESS
13:30 - 14:30 EDT (Boston)
Conferences
16Dec
2025
Year-end late-stage pipeline review
Sanofi is pleased to invite investors and analysts to participate in a year-end late-stage pipeline review by R&D management on Tuesday, December 16, 2025.
17:15 CET (11:15 EST)
Presentations
12Jan
2026

30th Consecutive Year of Dividend Increase

Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00
